{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.64","upperLimit":"85.46","value":"75.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by the investigator using the Lugano Classification.","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 2.5 months","title":"ORR by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}